Medication info
Rozalpin Plus Tablet

Rozalpin Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
SPC Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201405989 · Approved 2014.12.22 · Insurance code 669700180

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: The combination of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia at this dose despite blood pressure control: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose if creatinine clearance is 30 mL/min or greater. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment Use in these patients is not recommended because the initial dose of losartan potassium for patients with hepatic impairment requiring dosage adjustment, 25 mg, cannot be administered with this drug.
Child dose
Children and adolescents (under 18 years): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
SPC Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used in patients with hypertension whose blood pressure control is insufficient with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: The combination of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia at this dose despite blood pressure control: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose if creatinine clearance is 30 mL/min or greater. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment Use in these patients is not recommended because the initial dose of losartan potassium for patients with hepatic impairment requiring dosage adjustment, 25 mg, cannot be administered with this drug.

Child dose

Children and adolescents (under 18 years): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication may pose serious risks to the fetus and newborn, especially during pregnancy; therefore, administration should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with certain allergic reactions, severely impaired kidney or liver function, and in women who are pregnant or may become pregnant. Patients with health conditions such as hypotension, kidney problems, liver dysfunction, and electrolyte imbalance should use this medication with special caution. Blood pressure, kidney function, and electrolyte levels should be monitored regularly while using this medication to ensure there are no abnormalities. This medication can affect potassium levels; therefore, potassium supplements or potassium-rich foods should not be taken without consulting a doctor. This medication may cause skin sensitivity reactions and may increase the risk of skin cancer with sun exposure; therefore, care should be taken to protect the skin from sunlight. Symptoms such as dizziness or drowsiness may occur, so caution is required when driving or operating machinery. There may be interactions when this medication is taken with other drugs, so all medications being taken should be reported to the physician or pharmacist. Safety in children and adolescents has not been established, so it is recommended not to use this medication in these populations. Elderly patients may experience side effects more frequently, thus they should use this medication with greater caution. When storing this medication, keep it out of reach of children and store it in its original container to maintain its quality.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 127 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin peeling
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • second-degree AV block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorders
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neuroexcitability
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • agitation
  • renal failure
  • kidney dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that is protected from light, at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication and prevent degradation.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.